Abstract

MYCN is a member of the MYC family of proto-oncogenes. It encodes a transcription factor, MYCN, involved in the control of fundamental processes during embryonal development. The MYCN protein is situated downstream of several signaling pathways promoting cell growth, proliferation and metabolism of progenitor cells in different developing organs and tissues. Conversely, deregulated MYCN signaling supports the development of several different tumors, mainly with a childhood onset, including neuroblastoma, medulloblastoma, rhabdomyosarcoma and Wilms’ tumor, but it is also associated with some cancers occurring during adulthood such as prostate and lung cancer. In neuroblastoma, MYCN-amplification is the most consistent genetic aberration associated with poor prognosis and treatment failure. Targeting MYCN has been proposed as a therapeutic strategy for the treatment of these tumors and great efforts have allowed the development of direct and indirect MYCN inhibitors with potential clinical use.

Highlights

  • IntroductionThe MYC proto-oncogene family includes three paralogs: c-MYC, MYCN and MYCL [1,2]

  • The MYC proto-oncogene family includes three paralogs: c-MYC, MYCN and MYCL [1,2].They are situated on different chromosomes (Table 1) and are expressed at specific times during development, but encode proteins with similar functional domains, including the trans-activating and DNA binding domains (Figure 1) [1]

  • MYCN is important in cell cycle progression and apoptosis and it is the dysfunction of these processes due to amplification of the MYCN gene that contributes to aggressive medulloblastoma [151,153]

Read more

Summary

Introduction

The MYC proto-oncogene family includes three paralogs: c-MYC, MYCN and MYCL [1,2] They are situated on different chromosomes (Table 1) and are expressed at specific times during development, but encode proteins with similar functional domains, including the trans-activating and DNA binding domains (Figure 1) [1]. These proteins, c-MYC, MYCN and MYCL (here together referred to as “MYC”), are transcription factors that belong to a larger class of proteins which contain a basic-region/helix-loop-helix/leucine-zipper (bHLHZip) important for protein dimerization and sequence-specific DNA binding [3]. Aberrant MYC regulation can lead to increased cell proliferation and is commonly observed in cancers [2]

MYCN and the Cell Cycle
MYCN in Apoptosis and Cell Death
MYCN and Metabolism
MYCN and Embryonic Tumors
Neuroblastoma
Wilms’ Tumor
Retinoblastoma
Medulloblastoma
Rhabdomyosarcoma
Feingold Syndrome
Prostate Cancer
Basal Cell Carcinoma
Leukemia
Lung Cancer
MYCN as a Therapeutic Target
Targeting MYCN Transcription
Targeting MYCN Protein Stability
Targeting MYCN Dimerization and Transcriptional Activity
MYCN-Based Immunotherapy
Indirect Targeting of MYCN
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.